SpicyIP Critiques Editorial on Section 100 Misuse

SpicyIP Challenges Misreading of Section 100

In response to an Economic Times editorial titled 'Protect Patients and Patents Smartly', SpicyIP published a rebuttal arguing that the piece misrepresents Section 100 of the Patents Act, 1970, and perpetuates the false dichotomy between patent protection and access to medicines. The article asserts that judicial precedent consistently supports equitable access without undermining innovation incentives.

The critique highlights that Section 100 allows government use of patented inventions for public health purposes, with compensation mechanisms already embedded in law. Judicial interpretations—from the Supreme Court’s decision in Bayer v. Union of India to recent HC orders—have affirmed that such provisions do not equate to expropriation, but are lawful tools for ensuring access during health crises.

For practitioners, this underscores the importance of accurately framing public discourse around IP and health. Legal professionals must engage with both policy narratives and judicial reasoning to advocate for balanced enforcement. Misinformation in influential media can skew policy debates, making authoritative legal analysis from platforms like SpicyIP essential for grounding public understanding.